To deliver effective cancer therapy for more patients

Kenichi Shimada is a Research Associate in the Laboratory of Systems Pharmacology at Harvard Medical School (HMS) and has a joint appointment at the Ludwig Center and at the Breast Tumor Immunology Laboratory at Dana-Farber Cancer Institute (DFCI). He has a background in both molecular biology and computational biology. Kenichi received his Ph.D. for the elucidation of the mechanisms of ferroptosis, a form of non-apoptotic cell death phenotype, under the supervision of Dr. Brent Stockwell at Columbia Univeristy. In 2015, he came to HMS and continued his training as a postdoctoral fellow with Dr. Timothy Mitchison and has published a few papers in mechanistic toxicology and cancer signaling.

Since December 2020, Kenichi started to work with Drs. Elizabeth Mittendorf, Jennifer GuerrieroJoan Brugge, and Peter Sorger to elucidate tumor-intrinsic and extrinsic factors that predict clinical outcomes in breast cancer cohorts using single-cell transcriptome and multi-dimensional imaging.